Research

Hormonal

In type-2 diabetic patients, synthetic human GLP-1 [7-36 amide] retains significant insulinotropic activity and lowers glucagon, whereas synthetic human GIP loses its insulin-stimulating effectiveness.

For individuals with type-2 diabetes, medications that mimic GLP-1 (like semaglutide or liraglutide) are effective because they bypass the body's broken natural response to food. Unlike GIP, which stops working well in diabetes, GLP-1 continues to help produce insulin and lower glucagon, helping to control blood sugar without causing dangerous lows.

GoodQualifiesHIGH confidence
In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Michael A. Nauck et al. · Journal of Clinical Investigation · 1993

Why this rating

Randomized, controlled, crossover study with matched normal subjects and diabetic patients using hyperglycemic clamps, though sample size is small (n=9 per group).

Source

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck et al. · Journal of Clinical Investigation · 1993

DOI 10.1172/jci116186

crossover · n=18Cited 1,640×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →